If you’re in the field of molecular testing, we’ve got exciting news for you. A new retrospective study reveals major advantages of digital PCR (dPCR) over NGS for EGFR and KRAS mutation detection in non-small cell lung cancer (NSCLC) patient samples.
Faster turnaround time: Time is of the essence, and QIAcuity dPCR gets you results fast. With its fully automated workflow, QIAcuity dPCR ensures accurate detection of EGFR and KRAS mutations in a significantly shorter time when driver mutations are known.
User-friendly software: Make molecular testing accessible for your institution. QIAcuity dPCR simplifies the complex with automated signal detection and data analysis through user-friendly proprietary software. With QIAcuity, you can make dPCR part of your routine practice.
Consistent technical parameters: Whether conducting EGFR- or KRAS-based assays, QIAcuity dPCR demonstrated consistent technical sensitivity, specificity and concordance compared with NGS. This equates to reliable and accurate detection across different mutation types, and a streamlined testing process.
Ready to discover a new method for molecular testing? Get the full details in the article here.